Healthcare / Medical DevicesASX
$1.72
-0.04 (-2.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-6.3M · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$160M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-105.6%
↓Gross Margin
N/A
•Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-9.8M · FCF $-7.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-9.8M | $-9.8M | $-2.7M | $-3.9M | $-6.1M |
| EBITDA | $-7.9M | $-7.9M | $-1.5M | $-3.5M | $-5.8M |
| EPS | -0.11 | -0.11 | -0.03 | -0.05 | -0.08 |
| Balance Sheet | |||||
| Debt/Equity | 0.38 | 0.38 | 0.16 | 0.59 | 0.10 |
| Current Ratio | 12.94 | 12.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.9M | $-7.9M | $-6.3M | $646861.00 | $-4.0M |
| Returns | |||||
| ROE | -105.6% | -105.6% | -14.7% | -75.7% | -86.3% |
| Valuation | |||||
| P/B | 15.51 | 15.51 | 8.65 | 17.47 | 19.11 |
| Growth & Yield | |||||
| EPS Growth | -238.6% | -238.6% | 31.9% | 38.7% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.11
Residual
-1.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.